Phase 1RecruitingINTERVENTIONAL
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
ClinicalTrials.gov · NCT07723833 · Registry updated: 2026-09-16
- Condition / research focus
- Healthy Participants
- Sponsor
- AstraZeneca
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2026-07-27. Completion: 2026-11-18 (may be estimated). No results posted in this registry response.
Products and interventions (6)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Elecoglipron Reference Formulation Dose A (drug)
- Elecoglipron Test formulation 1 Dose A (drug)
- Elecoglipron Reference Formulation Dose B (drug)
- Elecoglipron Test formulation 1 Dose B (drug)
- Elecoglipron Test formulation 2 Dose A (drug)
- Elecoglipron Test formulation 2 Dose B (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Research Site
Glendale, California, United States
Site recruitment: Recruiting - Research Site
Brooklyn, Maryland, United States
Site recruitment: Recruiting